EP3105331

ALNYLAM PHARMACEUTICALS, INC.
Application Number
EP15705888A
Filing Date
Feb 11, 2015
Status
Granted And Under Opposition
May 21, 2021
Grant Date
Jun 23, 2021
External Links
Slate, Register

Biblio Summary

The patent EP3105331B1 was granted on Jun 23, 2021 by Alnylam Pharmaceuticals, Inc. The patent is currently Granted And Under Opposition.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GRUNECKER PATENT- UND RECHTSANWALTE PARTG MBBMar 23, 2022 N.A.

The table below shows the patents of Alnylam Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3366775Modified Rnai AgentsApr 27, 20221
EP3656860Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use ThereofApr 20, 20221
EP2723758Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use ThereofJun 20, 20181